Life Science News

First tazarotene lotion treatment for acne vulgaris, ARAZLO , now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans

Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) and its Canadian dermatology division, one of the largest prescription dermatology health care businesses in Canada, today announced that its new topical prescription treatment for acne vulgaris, ARAZLO TM (tazarotene lotion, 0.045% ww), is now available to patients through the provincial public drug plans of Quebec Ontario Alberta and Saskatchewan as well as the federal government's Non-Insured Health Benefits (NIHB) drug plan, which serves Canada's First Nations and Inuit populations. 1

Bausch Health, Canada Inc. (CNW Group/Bausch Health)

ARAZLO is the first tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older. 2 The listings by the four public drug plans are the first for ARAZLO in Canada , with others expected to follow as a result of the successful conclusion of listing negotiations with the pan-Canadian Pharmaceutical Alliance, representing the drug plans of the federal government and all provinces and territories.

"We are very pleased to have achieved agreements for these first public drug plan listings in Canada for ARAZLO," said Cees Heiman , Bausch Health, Senior Vice President, Europe and Canada .  "It is an important further step in helping to provide new treatment options for the approximately 5.6 million Canadians who are impacted by acne. 4 We are very proud to have a large dermatology portfolio to help meet Canadians' needs."

"While tazarotene is not a new retinoid, the vehicle in ARAZLO is a true innovation in topical technology and enhances the tolerability, and thus effectiveness, of this new product for acne patients," said Dr. Jerry Tan , MD, FRCPC, of Windsor, Ontario , President of the Acne and Rosacea Society of Canada , Adjunct Professor, Western University .

ARAZLO is the first tazarotene acne treatment available in a lotion formulated with PRISMATREX TM technology (formulation with known hydrating and moisturizing effects, which may alleviate dryness of skin) 2 and has been shown to provide a good tolerability profile. Retinoids like tazarotene are a core component of acne treatment. Providing the treatment in a lotion form helps limit the dryness and irritation that has historically been a barrier to the long-term use of tazarotene by patients. 3

About Acne Vulgaris
Acne vulgaris ("vulgaris" means "common") is the most common skin problem seen by doctors in Canada . It occurs when the pores of the skin become plugged with oil and skin cells, often causing whiteheads, blackheads, pimples or cysts to appear on the face, forehead, chest, upper back and shoulders. Acne affects about 5.6 million Canadians, or nearly 20 per cent of the population and causes emotional distress and can cause permanent scarring 2 or pigmentation changes. 5 Acne affects about 90 per cent of adolescents and about 25 per cent of teens will still have acne at age 25. 4

About ARAZLO TM
ARAZLO tazarotene lotion, 0.045% w/w is a topical prescription indicated for the topical treatment of acne vulgaris. ARAZLO can be used on affected areas in patients 10 years and older. The safety and efficacy of ARAZLO in children below the age of 10 years has not been established. 2

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Bausch Health, Canada Inc.'s prescription treatment portfolio is focused on dermatology -, gastrointestinal and cardio-metabolic conditions. Bausch Health also has two manufacturing facilities for prescription pharmaceuticals in Canada , in Laval, Quebec , and Steinbach, Manitoba . More information can be found at the Company's website at www.bauschhealth.ca .

REFERENCES

1 . Quebec :
https://www.ramq.gouv.qc.ca/SiteCollectionDocuments/professionnels/medicaments/tableau-nouveautes-innovateurs/tableau-nouveautes-innovateurs_2022-11-09.pdf assessed Nov. 18, 2022
Ontario :
https://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/summary_edition43_20221024.pdf

Alberta :
https://idbl.ab.bluecross.ca/idbl/drugDetails?_cid=3ea4d70e-b206-466a-a30b-82746e11ed08&id=0000099458&intchg_grp_nbr=1&detailId=7661580

Saskatchewan :
https://formulary.drugplan.ehealthsask.ca/Bulletins/Bulletin-0222-Nov-2022.pdf

NIHB :
https://nihb-ssna.express-scripts.ca/en/0205140506092019/16/160407

2. ARAZLO (Tazarotene Lotion) Product Monograph, July 7, 2021 .

3. "Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems." Pharmaceutics. Gemma Latter et al, October 2019 , https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835300/ , accessed Nov. 1, 2022 .

4. Canadian Dermatology Association, Acne, Quick Facts, https://dermatology.ca/public-patients/skin/acne/#:~:text=Acne%20affects%205.6%20million%20Canadians,adults%20ages%2020%20to%2040 , accessed Nov. 1, 2022 .

5. "What to Know about Hyperpigmentation Acne." Medical News Today , Jessica Caporuscio , April 28 , 2021, https://www.medicalnewstoday.com/articles/hyperpigmentation-acne , accessed Nov. 1, 2022 .

SOURCE Bausch Health

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2022/22/c9569.html

News Provided by Canada Newswire via QuoteMedia

BHC:CA,BHC
The Conversation (0)

Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility adjacent to UCSF Medical Center's Mission Bay campus.

The partnership between Thermo Fisher and UCSF, first announced in 2021 , has the potential to demonstrate that having scientists, clinicians, and patients closer to a manufacturing site may expedite the development of breakthrough treatments. UCSF's initial focus at the facility will be on treatments for glioblastoma, multiple myeloma, and other cancers using updated approaches to CAR-T and CRISPR technologies. Therapies for other difficult to treat conditions will follow.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Danaher Schedules First Quarter 2023 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2023 on Tuesday, April 25, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour. During the call, the company will discuss its financial performance, as well as future expectations.

The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com , under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic: Karen Parkhill on Empowering Women, Business Transformation

In her six years as chief financial officer at Medtronic, Karen Parkhill has helped advance women's representation at all levels of the company

She's proud of the progress. As of 2022, women make up 51% of Medtronic employees, 43% of managers and above, and 36% of its board of directors.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Knight Therapeutics Inc. ranks on The Globe and Mail's fourth-annual Women Lead Here benchmark of executive gender diversity

Knight Therapeutics Inc. (TSX: GUD) ("Knight" or "the Company") is pleased to announce it has been included on The Globe and Mail's 2023 Report on Business magazine's Women Lead Here list. This annual editorial benchmark identifies top-notch Canadian businesses with the highest executive gender diversity.

This benchmark was established in 2020 by Report on Business magazine and applies a proprietary research methodology to determine Canadian corporations with the highest degree of gender diversity among executive ranks. The ranking companies have made tangible and organizational progress related to executive gender parity.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  • TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023
  • Phase 2 proof-of-concept trial of farudodstat in alopecia areata expected to commence in the second quarter of 2023 with topline data readout expected in the first quarter of 2024
  • Expected cash runway extended through at least the second quarter of 2024 with recent $20 million in financing, with potential to receive up an additional $80 million

ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided an update on recent corporate activities.

"We ended 2022 and have begun 2023 achieving a number of milestones across our clinical pipeline that position ASLAN for strong momentum throughout this year and into 2024," said Dr Carl Firth, CEO, ASLAN Pharmaceuticals . "At the end of 2022, we commenced dosing atopic dermatitis (AD) patients in our dupilumab -experienced (TREK-DX) trial. Most notably, we completed enrollment at the start of 2023 in our TREK-AD Phase 2b trial, testing eblasakimab as a novel treatment for moderate-to-severe AD, and we look forward to reporting topline data from this study in early July 2023. In addition, we formed a collaboration with Thermo Fisher Scientific to manufacture a high concentration formulation of eblasakimab that will allow us to administer 400mg in a single subcutaneous injection with a range of different devices."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Medtronic Announces Pricing of $2.0 Billion of Senior Notes

Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), has priced an offering (the "Offering") of $1,000,000,000 principal amount of 4.25% senior notes due 2028 and $1,000,000 ,000 principal amount of 4.50% senior notes due 2033 (collectively, the "Notes").  All of Medtronic Luxco's obligations under the Notes will be fully and unconditionally guaranteed by the Company and Medtronic, Inc., a wholly-owned indirect subsidiary of Medtronic Luxco, on a senior unsecured basis.

The net proceeds of the Offering are expected to be used to repay indebtedness, which is expected to include a portion of the outstanding indebtedness under Medtronic Luxco's Japanese-yen denominated term loan agreement by and among Medtronic Luxco, the Company, Medtronic, Inc., and Mizuho Bank , Ltd. as administrative agent and as the lender and for general corporate purposes. The Offering is expected to close on March 30, 2023 , subject to customary closing conditions. The joint book-running managers for the Offering are Barclays Capital Inc., J.P. Morgan Securities LLC and Mizuho Securities USA LLC.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×